PHVS announces positive topline data from CHAPTER-3 study
Pharvaris says its CHAPTER-3 pivotal study of deucrictibant XR for prophylaxis of HAE attacks produced positive topline results.
Story updates
10:57:39 AM UTC
SquawkNews
The pivotal Phase 3 CHAPTER-3 study showed deucrictibant XR reduced HAE attack rates by 83% versus placebo, with strong efficacy across all HAE types and a favorable safety profile. Results support regulatory filings in 2027 and highlight the therapy's potential to improve disease control and quali…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.